GlassScriptPhysician profile
Hussain Muhammad Abdullah
NPI 1033646583
$1,611.87
in general payments reported to CMS, 2019-2025
23 companies · $714 in 2025
The $714 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $93.21 · 2023: $421 · 2024: $384 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.66 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $236.20 | 2022-2025 | Spravato, Invega Sustenna |
| Indivior INC. | $215.23 | 2022-2025 | Sublocade, Perseris |
| Corium, LLC | $143.17 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $142.25 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Neurocrine Biosciences, INC. | $130.85 | 2024-2025 | Ingrezza |
| Braeburn INC. | $112.37 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $111.77 | 2023-2025 | Cobenfy, Eliquis |
| Supernus Pharmaceuticals, INC. | $101.35 | 2025 | Qelbree |
| Alkermes, INC. | $100.46 | 2023-2025 | Vivitrol, Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $45.15 | 2023-2025 | Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $32.81 | 2025 | Fanapt |
| Lundbeck LLC | $29.50 | 2023 | Rexulti |
| Bioxcel Therapeutics, INC. | $22.98 | 2024 | Igalmi |
| Tempus Ai, INC | $22.82 | 2024 | |
| Lilly USA, LLC | $22.50 | 2025 | Kisunla, Amyvid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $22.14 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.36 | 2025 | Caplyta |
| Harmony Biosciences LLC | $20.64 | 2023 | Wakix |
| Neos Therapeutics, LP | $17.95 | 2025 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $16.36 | 2023 | Auvelity |
| Eisai INC. | $15.53 | 2023 | |
| Ironshore Pharmaceuticals INC. | $14.48 | 2024 | |
| Hikma Pharmaceuticals USA | $14.00 | 2023 | Kloxxado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussain Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.